Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.
Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.
Int J Mol Sci. 2021 Aug 30;22(17):9386. doi: 10.3390/ijms22179386.
Adipocyte fatty acid-binding protein (A-FABP), which is also known as ap2 or FABP4, is a fatty acid chaperone that has been further defined as a fat-derived hormone. It regulates lipid homeostasis and is a key mediator of inflammation. Circulating levels of A-FABP are closely associated with metabolic syndrome and cardiometabolic diseases with imminent diagnostic and prognostic significance. Numerous animal studies have elucidated the potential underlying mechanisms involving A-FABP in these diseases. Recent studies demonstrated its physiological role in the regulation of adaptive thermogenesis and its pathological roles in ischemic stroke and liver fibrosis. Due to its implication in various diseases, A-FABP has become a promising target for the development of small molecule inhibitors and neutralizing antibodies for disease treatment. This review summarizes the clinical and animal findings of A-FABP in the pathogenesis of cardio-metabolic diseases in recent years. The underlying mechanism and its therapeutic implications are also highlighted.
脂肪细胞脂肪酸结合蛋白（A-FABP），也称为 ap2 或 FABP4，是一种脂肪酸伴侣蛋白，也被进一步定义为脂肪衍生的激素。它调节脂质稳态，是炎症的关键介质。循环 A-FABP 水平与代谢综合征和心血管代谢疾病密切相关，具有明确的诊断和预后意义。大量动物研究阐明了涉及这些疾病中 A-FABP 的潜在潜在机制。最近的研究表明，它在调节适应性产热中的生理作用及其在缺血性中风和肝纤维化中的病理作用。由于其在各种疾病中的作用，A-FABP 已成为开发小分子抑制剂和中和抗体用于疾病治疗的有前途的靶标。本综述总结了近年来 A-FABP 在心脏代谢疾病发病机制中的临床和动物研究结果。还强调了潜在的机制及其治疗意义。
